News | Digital Pathology | April 09, 2019

Deep Lens Closes Series A Financing for Digital AI Pathology Platform

VIPER platform designed to aid with clinical trial recruitment at the time of diagnosis

Deep Lens Closes Series A Financing for Digital AI Pathology Platform

April 9, 2019 — Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further expand the company’s artificial intelligence (AI) and platform product development activities. Deep Lens is focused on AI-driven digital pathology for clinical trial recruitment at the time of diagnosis.

The financing was led by Northpond Ventures. Existing investors Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners also participated in this round, which comes just three months after Deep Lens closed its VC-led seed equity round. Funding to date now totals $17.5 million.

The company’s flagship technology, called VIPER (Virtual Imaging for Pathology Education and Research), was originally developed for research purposes in Columbus, Ohio. There it was the de-facto platform for global oncology studies including The Cancer Genome Atlas Project (TCGA) and others, before being commercialized by Deep Lens. VIPER combines AI with advanced pathology workflows, while also facilitating peer-to-peer collaboration and patient identification for clinical trials. The ultimate aim is to provide users with fast and accurate information, along with expert consultation, for better patient care and advanced clinical research.

Patient recruitment for clinical trials remains a time-intensive, costly barrier to the execution of drug development programs. More than 14,000 oncology clinical trials are actively recruiting patients1, yet estimates put the rate of participation as low as 3 percent of potential trial candidates.2 Deep Lens’ VIPER platform enables the pathologist in clinical trial recruitment. By identifying eligible patients at the time of their diagnosis, much sooner than current methods, VIPER can help fast-track trial enrollment and potentially shorten the duration of the trial.

For more information: www.deeplens.ai

References

1. https://clinicaltrials.gov, Last accessed February 28, 2019

2. https://www.ncbi.nlm.nih.gov/books/NBK50895/

Related Content

Sectra Providing Centralized Regional Solution for Digital Pathology in the U.K.
News | Digital Pathology | June 14, 2019
Sectra has signed a five-year contract with North Tees and Hartlepool National Health System (NHS) Foundation Trust for...
M*Modal and Community Health Network Partner on AI-powered Clinical Documentation
News | PACS Accessories | June 13, 2019
M*Modal announced that the company and Community Health Network (CHNw) are collaborating to transform the patient-...
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
The Current Direction of Healthcare Reform Explained by CMS Administrator Seema Verma
News | Radiology Business | June 11, 2019
June 11, 2019 — Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma addressed the American Med
Aidoc Earns FDA Approval for AI for C-spine Fractures
Technology | Artificial Intelligence | June 11, 2019
Radiology artificial intelligence (AI) provider Aidoc announced the U.S. Food and Drug Administration (FDA) has cleared...
Medivis SurgicalAR Gets FDA Clearance
Technology | Virtual and Augmented Reality | June 10, 2019
Medivis announced that its augmented reality (AR) technology platform for surgical applications, SurgicalAR, has...
Glassbeam Announces New Clinsights Application Suite for Healthcare Provider Market
Technology | Analytics Software | June 10, 2019
Glassbeam launched Clinsights, a new revitalized application suite powered by artificial intelligence/machine learning...
The DeepAAA algorithm, developed at the MGH & BWH Center for Clinical Data Science, accurately detected and measured an abdominal aortic aneurysm (AAA) in a CT image even though appearance of the AAA was complicated by a blood clot

The DeepAAA algorithm, developed at the MGH & BWH Center for Clinical Data Science, accurately detected and measured an abdominal aortic aneurysm (AAA) in a CT image even though appearance of the AAA was complicated by a blood clot. (The algorithm drew a green circle around the aneurysm.) Image courtesy of Varun Buch, MGH & BWH Center for Clinical Data Science

Feature | Artificial Intelligence | June 10, 2019 | By Greg Freiherr
Editor’s note: This article is the second in a content series by Greg Freiherr covering the ...
Volpara Health Technologies to Acquire MRS Systems Inc.
News | Mammography Reporting Software | June 04, 2019
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based...
SIIM and ACR Host Machine Learning Challenge for Pneumothorax Detection and Localization
News | Artificial Intelligence | June 03, 2019
The Society for Imaging Informatics in Medicine (SIIM) and the American College of Radiology (ACR) are collaborating...